Shekarchi Maral, Navidpour Latifeh, Rajabi Khorami Afshin, Shekarchi Mahtab, Partoazar Alireza, Shafaroodi Hamed, Rahmanipour Narges, Shafiee Abbas, Shekarchi Maryam
Department of Chemistry, School of science, karaj Branch, Islamic Azad University, Karaj, Iran.
Iran J Pharm Res. 2011 Spring;10(2):369-77.
Diclofenac sodium has been used for its anti-inflammatory actions for about 28 years, but since all the non-steroidal anti-inflammatory drugs (NSAIDs) suffer from the lethal gastro intestinal (GI) toxicities, diclofenac sodium is not an exception. The free -COOH group is thought to be responsible for the GI toxicity associated with all traditional NSAIDs. In the present research, the main motto was to develop new chemical entities as potential anti-inflammatory agents with no GI toxicities. A new type of 2-(2-phenoxyphenyl) acetohydrazide possessing N-arylidene substituents, was synthesized for evaluation as anti-inflammatory agents. The starting material 2-(2-Phenoxyphenyl) acetohydrazide was synthesized from 2-phenoxybenzoic acid in several steps according to the previous published method. Various substituted arylidene-2-phenoxynicotinic acid hydrazide derivatives were synthesized by the reaction of hydrazide 17 with selected aldehydes and screened for their potential anti-inflammatory activity. The structure of synthesized compounds was confirmed by different nuclear magnetic resonance technique, Fourier transform infrared spectroscopy (FTIR) and Mass-spectrometry data format. Qualitative structure-activity relationship data, acquired using the carrageenan-induced rat paw edema assay, showed that this group of arylidene-2-phenoxybenzoic acid hydrazides exhibit anti-inflammatory activity with significant reduction of rat paw edema (17-58% reduction in inflammation at different time intervals) in comparison with control group and a moderate to good activity range in comparison with diclofenac as the reference drug. Compounds 9a, 9d and 9e exhibited the most prominent and consistent anti-inflammatory activity. The compound, N-(4-Chlorobenzylidene)-2-(2-phenoxyphenyl) acetohydrazide (9d), exhibited the most in-vivo activity (32-58% reduction in inflammation) compared to the reference drug diclofenac (35-74% reduction in inflammation) in a carrageenan induced rat paw-edema assay.
双氯芬酸钠因其抗炎作用已被使用约28年,但由于所有非甾体抗炎药(NSAIDs)都存在致命的胃肠道(GI)毒性,双氯芬酸钠也不例外。游离的 -COOH基团被认为是所有传统NSAIDs相关胃肠道毒性的原因。在本研究中,主要目标是开发新的化学实体作为潜在的抗炎剂且无胃肠道毒性。合成了一种新型的具有N - 亚芳基取代基的2-(2 - 苯氧基苯基)乙酰肼,用于评估其作为抗炎剂的活性。起始原料2-(2 - 苯氧基苯基)乙酰肼根据先前发表的方法分几步从2 - 苯氧基苯甲酸合成。通过酰肼17与选定的醛反应合成了各种取代的亚芳基 - 2 - 苯氧基烟酸酰肼衍生物,并对其潜在的抗炎活性进行了筛选。通过不同的核磁共振技术、傅里叶变换红外光谱(FTIR)和质谱数据格式确认了合成化合物的结构。使用角叉菜胶诱导的大鼠足爪水肿试验获得的定性构效关系数据表明,与对照组相比,这组亚芳基 - 2 - 苯氧基苯甲酸酰肼表现出抗炎活性,大鼠足爪水肿显著减轻(在不同时间间隔炎症减轻17 - 58%),与作为参考药物的双氯芬酸相比,活性范围为中等至良好。化合物9a、9d和9e表现出最突出和一致的抗炎活性。在角叉菜胶诱导的大鼠足爪水肿试验中,化合物N-(4 - 氯亚苄基)-2-(2 - 苯氧基苯基)乙酰肼(9d)与参考药物双氯芬酸(炎症减轻35 - 74%)相比,表现出最强的体内活性(炎症减轻32 - 58%)。